Breast Cancer: Epidemiology and Etiology

Breast cancer, the most frequently occurring cancer in women, is a major public health problem, with 1,384,155 estimated new cases worldwide with nearly 459,000 related deaths. Breast cancer is highly heterogeneous in its pathological characteristics, some cases showing slow growth with excellent prognosis, while others being aggressive tumors. Current predictions and statistics suggest that both worldwide incidence of breast cancer and related mortality are on the rise. According to 2012 GLOBOCAN statistics, nearly 1.7 million women were diagnosed with breast cancer with 522,000 related deaths—an increase in breast cancer incidence and related mortality by nearly 18 % from 2008. According to American Cancer Society, one in eight women in the United States will develop breast cancer in her lifetime. It has been predicted that the worldwide incidence of female breast cancer will reach approximately 3.2 million new cases per year by 2050. These numbers reflect the magnitude of breast cancer incidence, its effect on society worldwide and the need for urgency for preventive and treatment measures. While technological advances in medical sciences and health care have made it possible to detect the disease early and to start the treatment early on to prevent the progress of the disease into a metastatic state, there are several unanswered questions with regard to the molecular mechanisms that underlie the aggressiveness of certain forms of this disease. Epidemiological studies suggest that addressing socio economical issues is utmost important, so that all women have equal access to medical care from screening to advanced treatment, and only such decisive action can help reduce the worldwide burden of breast cancer.

[1]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[2]  Cheng Lu,et al.  Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis , 2013, Breast Cancer Research and Treatment.

[3]  Kornelia Polyak,et al.  Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer , 2010, Clinical Cancer Research.

[4]  X. Puente,et al.  Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. , 2008, Cancer research.

[5]  V. McCormack,et al.  Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Narod,et al.  Pattern of metastatic spread in triple-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[7]  Rongwei Fu,et al.  Risk Factors for Breast Cancer for Women Aged 40 to 49 Years , 2012, Annals of Internal Medicine.

[8]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[9]  H. Nelson,et al.  Risk Factors for Breast Cancer for Women Aged 40 to 49 Years , 2012, Annals of Internal Medicine.

[10]  O. Olopade,et al.  Breast cancer genetics in African Americans , 2003, Cancer.

[11]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[12]  Ahmedin Jemal,et al.  Trends in Breast Cancer by Race and Ethnicity: Update 2006 , 2006, CA: a cancer journal for clinicians.

[13]  A. Jemal,et al.  Breast Cancer Statistics , 2013 .

[14]  J. Chang-Claude,et al.  Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. , 2013, Clinical chemistry.

[15]  Michael J Kerin,et al.  Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer , 2010, Annals of surgery.

[16]  Ahmedin Jemal,et al.  Breast cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[17]  V. Ambros,et al.  MicroRNA Pathways in Flies and Worms Growth, Death, Fat, Stress, and Timing , 2003, Cell.

[18]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[19]  A. Jemal,et al.  Breast cancer statistics, 2013 , 2014, CA: a cancer journal for clinicians.

[20]  Guan-li Huang,et al.  Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. , 2009, Oncology reports.

[21]  M. Espié,et al.  Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer , 2002, Oncogene.

[22]  A. Korlimarla,et al.  The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women , 2012, Tumor Biology.

[23]  J. Jones,et al.  Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer. , 2012, British medical bulletin.

[24]  R. Prentice,et al.  Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. , 2011, Journal of the National Cancer Institute.

[25]  C. Hudis,et al.  Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer , 2012, The breast journal.

[26]  Graham A. Colditz,et al.  Trends in breast cancer incidence and mortality in the United States: implications for prevention , 2013, Breast Cancer Research and Treatment.

[27]  P. Morris,et al.  Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[28]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Iwanaga,et al.  Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. , 2002, Cancer research.

[30]  Nilanjan Chatterjee,et al.  Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database , 2002, Breast Cancer Research and Treatment.

[31]  E. van Limbergen,et al.  Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer , 2005, Journal of Clinical Pathology.

[32]  M. Kogevinas,et al.  Socioeconomic differences in cancer survival: a review of the evidence. , 1997, IARC scientific publications.

[33]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[34]  S. Duffy,et al.  Matrix Metalloproteinase Single-Nucleotide Polymorphisms and Haplotypes Predict Breast Cancer Progression , 2007, Clinical Cancer Research.

[35]  H. Tsuda,et al.  Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society , 2010, Breast cancer.

[36]  Qiong Shao,et al.  MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.

[37]  L. Zelek,et al.  Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies , 2012, Breast Cancer Research and Treatment.

[38]  K. Michels,et al.  Epigenetic epidemiology of cancer. , 2014, Biochemical and biophysical research communications.

[39]  J. Aitken,et al.  Childhood cancer mortality in Australia. , 2012, Cancer epidemiology.

[40]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[41]  I. Bleiweiss,et al.  Stage 0 to stage III breast cancer in young women. , 2000, Journal of the American College of Surgeons.

[42]  A. C. Pereira,et al.  Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. , 2007, Cancer research.

[43]  Wanqing Chen,et al.  Breast cancer in China. , 2014, The Lancet. Oncology.

[44]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[45]  Dino Amadori,et al.  The global breast cancer burden: variations in epidemiology and survival. , 2005, Clinical breast cancer.